85 related articles for article (PubMed ID: 19832927)
1. Cutaneous side effects of inhibition of VEGF signal transduction.
Wozel G; Sticherling M; Schön MP
J Dtsch Dermatol Ges; 2010 Apr; 8(4):243-9. PubMed ID: 19832927
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
3. [Anti-angiogenesis targeting drugs: a review].
Jia K; Li J
Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
6. Emerging targeted therapies for breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
[TBL] [Abstract][Full Text] [Related]
7. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
8. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Tonra JR; Hicklin DJ
Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
[TBL] [Abstract][Full Text] [Related]
9. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor trap in non small cell lung cancer.
Riely GJ; Miller VA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4623-7. PubMed ID: 17671153
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
12. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
14. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
15. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
17. Skin reactions to the new biologic anticancer drugs.
Myskowski PL; Halpern AC
Curr Opin Support Palliat Care; 2009 Dec; 3(4):294-9. PubMed ID: 19797958
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
19. [Angiogenesis and lung cancer].
Pérol M; Arpin D
Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E.
Shibuya M
Endothelium; 2006; 13(2):63-9. PubMed ID: 16728325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
